Orphalan announces trientine tetrahydrochloride non-inferior to d-Penicillamine in the maintenance treatment of Wilson’s Disease

In the Phase 3 CHELATE study (n=53), more patients receiving trientine tetrahydrochloride than d-Penicillamine achieved the primary endpoint of non-ceruloplasmin copper levels and 24-hour urinary copper excretion within therapeutic target ranges with (50% vs 24%, respectively).

Source:

Biospace Inc.